Denosumab: First data and ongoing studies on the prevention of bone metastases

Recent Results in Cancer Research

Volumn 192, Issue , 2012, Pages 187-196

  Von Moos, Roger ^a   Skacel, Tomas ^b,c  

^a KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

^b CHARLES UNIVERSITY   (Czech Republic)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CELL RECEPTOR; DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; PROSTATE SPECIFIC ANTIGEN; RANK RECEPTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ADJUVANT THERAPY; ARTICLE; BONE DESTRUCTION; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CASTRATION RESISTANT PROSTATE CANCER; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HIGH RISK PATIENT; HUMAN; HYPOCALCEMIA; JAW OSTEONECROSIS; LUNG CANCER; METASTASIS FREE SURVIVAL; NEPHROTOXICITY; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; SIDE EFFECT; VISCERAL METASTASIS;

EID: 84858189204     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-21892-7_9     Document Type: Article

References (30)

1. Armstrong AP (2008) RANKL Acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumour metastatic genes. Prostate 68:92-104
2. Canon J et al (2008a) The RANKL inhibitor OPG-Fc delays the de novo establishment of breast cancer skeletal metastases in an MDA-MB-231 mouse model. Cancer Treat Rev 34:S60
3. Canon J et al (2008b) Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 25(2): 119-129
4. Clines GA, Guise TA (2008) Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med 10:e7
5. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27(3):165-176 (Pubitemid 32452017)
6. Coleman R (2007) Potential use of bisphosphonates in the prevention of metastases in early-stage breast cancer. Clin Breast Cancer 7(Suppl 1):S29-S35 (Pubitemid 47325657)
7. European Medicines Agency (2010) Prolia (Denosumab) summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Informaion/human/001120/WC500093526.pdf
8. European Medicines Agency (2011) XGEVA (Denosumab) summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/ocument-library/EPAR- Product-Information/human/002173/WC500110381.pdf
9. Feeley BT, Liu NQ et al (2006) Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J Bone Miner Res 21(10):1571-1580 (Pubitemid 44484602)
10. Gonzalez-Suarez E et al (2006) Overexpression of RANK in the Mouse mammary gland increases proliferation and susceptibility to chemically induced mammay tumors. Breast Cancer Res Treat 100:S23 (Abstract 24)
11. Gonzalez-Suarez E, Jacob AP et al (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468(7320):103-107
12. Guise TA, Mundy GR (1998) Cancer and bone. Endocr Rev 19(1):18-54 (Pubitemid 29122073)
13. Kitazawa S, Kitazawa R (2002) RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198(2):228-236 (Pubitemid 35243881)
14. Jones DH, Nakashima T et al (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440(7084):692-696
15. Koch L (2011) Cancer: RANKL inhibition-a new weapon against breast cancer. Nat Rev Endocrinol 7(1):2
16. Lipton A et al (2010) Comparison of denosumab versus zoledronic acid (ZA) for treatment of bone metastases in advanced cancer patients: an integrated analysis of 3 pivotal trials (Abstract 1249P). Ann Oncol 21(Suppl 8): viii 379
17. Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2(8):584-593 (Pubitemid 37328925)
18. Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350(16):1655-1664
19. Santini D, Schiavon G et al (2011) Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS One 6:e19234
20. Scagliotti G, Hirsh V et al (2011) Overall survival improvement in patients with lung cancer treated with denosumab versus zoledronic acid: results from a randomised phase 3 study. J Thor Oncol 6 (6 (Suppl 2)): S273 (Abstract O01.01)
21. Schramek D, Leibbrandt A et al (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468(7320):98-102
22. Smith MR, Egerdie B et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361(8):745-755
23. Smith M, Saad F et al (2011) Denosumab to prolong bone metastasis-free survival in men with castrate-resistant prostate cancer: results of a global phase 3, randomized, double-blind trial. American Urological Association annual meeting. Washington, DC, USA
24. Swissmedic (2010) Authorised medicinal products. http://www.swissmedic. ch/zulassungen/00171/00181/01382/index.html?lang=en
25. Tan W, Zhang W et al (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signaling. Nature 470(7335):548-553
26. Thomas D, Henshaw R et al (2010) Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol 11(3):275-280
27. United States Federal Drugs Agency (2011a) Denosumab (Prolia) prescribing information USA. http://pi.amgen.com/united-states/prolia/prolia-pi.pdf
28. United States Federal Drugs Agency (2011b) Denosumab (XGEVA) Prescribing Information USA http://pi.augen.com/united.states/xgeva/xgeva.pi.pdf van der
29. Pluijm G, Que I et al (2005) Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res 65(17):7682-7690 (Pubitemid 41297242)
30. Zhang J, Dai J et al (2003) Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 63(22):7883-7890 (Pubitemid 37466723)